IP Library Granted Patent US 9,795,311
Granted Patent B2
US 9,795,311 · App. 15/355,616 · Granted Oct 24, 2017

Method for intraluminal pressure detection for diverticular disease

Inventors: Himanshu Mishra (Uttar Pradesh, IN); Mona Sharma (Madhya Pradesh, IN); Mandar Shirish Dixit (Uttar Pradesh, IN)
Assignee: EMPIRE TECHNOLOGY DEVELOPMENT LLC
A61B5/03A61B5/4255A61K9/0053A61K9/2072A61K9/4816A61K9/4825A61K9/4833A61K9/4866A61K9/4891A61K47/32A61K47/38G01L1/00G01M3/02G01N33/493A61B2562/0247A61B2562/162
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,795,311
App. No.
15/355,616
Granted
Oct 24, 2017
Kind
B2
Abstract

A pressure detection tablet is disclosed. The tablet is a capsule including a dye encapsulated within an inner coating, in which the inner coating is configured to rupture at a pressure equal to or greater than a pressure threshold. The tablet further includes an outer coating surrounding the capsule, in which the outer coating is configured to provide delivery of the capsule to a targeted site. The dye may be a non-metabolized, water soluble dye, such that a ruptured capsule releases the dye which can be visually detected in the urine. In some embodiments, the disclosure provides a method of making the tablet, using the tablet to detect peak pressure in the colon and reducing the risk of developing a colonic disorder.

Claims (28)

1. A method for estimating a peak pressure within the colon of a subject, the method comprising:

providing a pressure detection tablet comprising a capsule, wherein the capsule comprises:

a water-soluble and non-metabolizable dye encapsulated within an inner coating, wherein the inner coating is configured to rupture at a pressure equal to or higher than a pressure threshold, and

an outer coating surrounding the capsule, wherein the dye is absorbed by the colon and excreted by the kidneys in urine upon rupture of the inner coating;

orally administering the pressure detection tablet to the subject;

observing a color of the subject's urine after a test period; and

estimating the peak pressure within the colon of the subject during the test period based on the color of the subject's urine.

2. The method of claim 1 , wherein the outer coating is configured to provide targeted delivery of the capsule to the colon.

3. The method of claim 1 , wherein a normal urine color is indicative of the peak pressure within the colon being lower than the pressure threshold and a urine color attributable to the dye is indicative of the peak pressure within the colon being equal to or higher than the pressure threshold.

4. The method of claim 1 , wherein the inner coating comprises a pressure-sensitive polymer, and wherein the pressure threshold of the inner coating is selectable based on variations in at least one of a thickness, density and elasticity of the inner coating.

5. The method of claim 1 , wherein the outer coating comprises a pH sensitive polymer that is insoluble at the acidic pH of the stomach and proximal small intestine and comprises a copolymer of EUDRAGIT L and EUDRAGIT S polymers and formulated to dissolve at a neutral pH, or comprises azo polymers of styrene and 2-hydroxy methyl acrylate formulated to dissolve by bacterial degradation, or comprises a combination thereof.

6. The method of claim 1 , wherein the tablet comprises at least two capsules surrounded by the outer coating and wherein the at least two capsules comprise different dyes and are configured to rupture at equal to or higher than a different pressure threshold from one another.

7. The method of claim 1 , wherein the dye is water-soluble and non-metabolizable.

8. The method of claim 1 , wherein the outer coating comprises a pH sensitive polymer that is insoluble at the acidic pH of the stomach and proximal small intestine.

9. The method of claim 1 , wherein the pressure detection tablet comprises at least two capsules surrounded by the outer coating, and wherein the at least two capsules comprise different dyes and are configured to rupture at equal to or higher than a different pressure threshold from one another.

10. The method of claim 1 , further comprising administering a treatment to the subject if the peak pressure within the colon is equal to or above a pressure threshold, wherein the treatment is selected to reduce the peak pressure within the colon to below the pressure threshold.

11. The method of claim 10 , wherein the treatment reduces the risk of the colonic disorder.

12. The method of claim 10 , wherein the outer coating comprises a pH sensitive polymer that is insoluble at the acidic pH of the stomach and small intestine, and formulated to dissolve at a neutral pH or by bacterial degradation thereby providing a targeted delivery of the capsule to the colon.

13. The method of claim 10 , wherein estimating the peak pressure within the colon of the subject during the test period based on the color of the subject's urine comprises:

determining the peak pressure is below the pressure threshold during the test period in response to observing a normal urine color; and

determining the peak pressure is equal to or above the pressure threshold during the test period in response to observing a urine color attributable to the dye.

14. The method of claim 10 , wherein the pressure detection tablet comprises at least two capsules surrounded by the inner coating, and wherein the at least two capsules comprise different dyes and are configured to rupture at a different pressure threshold from one another.

15. The method of claim 10 , wherein the method is repeated daily, biweekly, weekly, bimonthly, monthly, yearly, or as required.

16. The method of claim 10 , wherein administering the treatment comprises administering a medication.

17. The method of claim 10 , wherein administering the treatment comprises administering at least one of an altered diet or a physical exercise regimen.

18. The method of claim 10 , wherein the inner coating comprises a pressure-sensitive ethyl cellulose polymer and the pressure threshold for rupture of the inner coating is selectable based on variations in at least one of a thickness, density and elasticity of the inner coating, and wherein the outer coating comprises a pH sensitive polymer that is formulated to be insoluble at the acidic pH of the stomach and proximal small intestine but formulated to dissolve at a neutral pH, or formulated to dissolve by bacterial degradation, or formulated to be a combination thereof.

19. The method of claim 10 , wherein the pressure threshold can range from about 200 mm Hg to about 700 mm Hg.

20. The method of claim 1 , wherein the outer coating comprises azo polymers of styrene and 2-hydroxy methyl acrylate, formulated to dissolve by bacterial degradation.

Assignments (3)
RELEASE OF SECURITY INTEREST IN PATENTS, RECORDED ON JANUARY 29, 2019, AT REEL/FRAME 048373/0217 Recorded Jun 22, 2026
From: CRESTLINE DIRECT FINANCE, L.P., AS COLLATERAL AGENT
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 075799/0053 →
RELEASE OF SECURITY INTEREST IN PATENTS, RECORDED ON JANUARY 29, 2019 AT REEL 048373 FRAME 0217 Recorded Sep 22, 2025
From: CRESTLINE DIRECT FINANCE, L.P., AS COLLATERAL AGENT
To: EMPIRE TECHNOLOGY DEVELOPMENT LLC
Reel/Frame 072936/0464 →
SECURITY INTEREST Recorded Jan 29, 2019
From: EMPIRE TECHNOLOGY DEVELOPMENT LLC
To: CRESTLINE DIRECT FINANCE, L.P.
Reel/Frame 048373/0217 →
Priority Claims (1)
IN 2359/DEL/2014 · Aug 20, 2014 · national
Continuity (2)
Division 14830547 · Aug 19, 2015
Related Publication 20170065192A1 · Mar 9, 2017